APA (7th ed.) Citation

B, H., & E, H. (2021). [Treatment of nonmetastatic CRPC: Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis]. Der Urologe. Ausg. A, 60(6), 753. https://doi.org/10.1007/s00120-021-01473-0

Chicago Style (17th ed.) Citation

B, Hadaschik, and Hellmis E. "[Treatment of Nonmetastatic CRPC: Androgen Receptor Inhibition as New Treatment Standard in Nonmetastatic Castration-resistant Prostate Cancer with High Risk of Metastasis]." Der Urologe. Ausg. A 60, no. 6 (2021): 753. https://doi.org/10.1007/s00120-021-01473-0.

MLA (9th ed.) Citation

B, Hadaschik, and Hellmis E. "[Treatment of Nonmetastatic CRPC: Androgen Receptor Inhibition as New Treatment Standard in Nonmetastatic Castration-resistant Prostate Cancer with High Risk of Metastasis]." Der Urologe. Ausg. A, vol. 60, no. 6, 2021, p. 753, https://doi.org/10.1007/s00120-021-01473-0.